CXCR4, CXCR7 and CXCL12 expression is not a prognostic predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 t...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Striefler
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors J. Striefler1, L. Wislocka1, M. Sinn1, U. Pelzer1, C. Denkert2, A. Juehling1, S. Bischoff3, M. Bahra4, B. Hendrik2, H. Oettle5, H. Riess6, P. Lohneis2
  • 1Charité – Universitätsmedizin Berlin, Department of Medical Oncology and Haematology, Berlin, Germany, /
  • 2Charité – Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany, /
  • 3Charité – Universitätsmedizin Berlin, CONKO Study Group, Berlin, Germany, /
  • 4Charité – Universitätsmedizin Berlin, Department of General, Visceral and Transplantation Surgery, Berlin, Germany, /
  • 5Outpatient Department Hematology/Oncology, Friedrichshafen, Germany, /
  • 6Charité-Universitätsmedizin Berlin, Berlin, Germany, /


Pancreatic cancer is a disease with a dismal prognosis. Several biomarkers have been tested in heterogeneous patient groups. Our aim was to evaluate the expression of the chemokine receptors CXCR4, CXCR7 and their common ligand CXCL12 as predictive and/or prognostic factors of adjuvant chemotherapy with gemcitabine and to evaluate their association with type of metastases.